RBC
BLCM

Ronald Blue & Co’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Ronald Blue & Co’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$117K Buy
+1,000
New +$124K ﹤0.01% 236

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Ronald Blue & Co's BLCM Position: Q2 2017 in Review

Ronald Blue & Co opened a new position in Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2017: 1,000 shares worth $117K. The stake represents ﹤0.01% of the portfolio and ranks #236 among its holdings.

84 funds tracked by Wall St. Rank hold BLCM as of Q2 2017.

  • Ronald Blue & Co held 1,000 shares of Bellicum Pharmaceuticals, Inc. worth $117K as of Q2 2017.
  • Bellicum Pharmaceuticals, Inc. was a new Ronald Blue & Co position in Q2 2017.
  • Bellicum Pharmaceuticals, Inc. made up ﹤0.01% of Ronald Blue & Co's portfolio in Q2 2017, its #236 holding.
  • 84 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2017.

Based on Ronald Blue & Co's 13F filing for Q2 2017, filed 28 Jul 2017.